Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma.

Cancer treatment and research communications - 1 Jan 2026

Lee Yixuan, Lim Nicole-Ann, Kwan Rowena Lee Ying, Chan Jason Yongsheng

Abstract excerpt

Tumor-agnostic therapies focus on shared molecular biomarkers independent of tissue of origin, allowing a single drug to target a common biomarker across different tumor types. Such targets with regulatory drug approvals include NTRK fusion, RET fusion, BRAF V600E mutation, FGFR1 rearrangement, HER2 overexpression, microsatellite instability or mismatch repair deficiency (MSI-H/dMMR), and high tumor mutational...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to ALK gene
Share to FGFR1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to NRG1 gene

Share to TP53 gene

Share to Lymphoma

Share to Mutation

Share to Precision Medicine

Source

Identifiers

PMID: 42401005
DOI: 10.1016/j.ctarc.2026.101312

Genes

ALK
BRAF
FGFR1
KRAS
MTAP
NRG1
RET
TP53

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma.PMID 42401005Read ↗

Precision therapy for lymphoma--current state and future directions.Semantic proximity Read ↗

Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing.Semantic proximity Read ↗

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right GenomicsSemantic proximity Read ↗

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.Semantic proximity Read ↗

[Histology-agnostic tumor treatment - a farewell to tumor entities?]Semantic proximity Read ↗

Towards precision medicine in lymphoid malignanciesSemantic proximity Read ↗

Special report: multiple molecular testing of cancers to identify targeted therapies.Semantic proximity Read ↗

Predictive and prognostic molecular biomarkers in lymphomas.Semantic proximity Read ↗

Impact of tissue-agnostic approvals for patients with gastrointestinal malignanciesSemantic proximity Read ↗

A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Semantic proximity Read ↗

The Future of Cancer Diagnosis and Treatment: Unlocking the Power of Biomarkers and Personalized Molecular-Targeted TherapiesSemantic proximity Read ↗

Molecular Monitoring of Lymphomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.